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SUPPLEMENTARY INFORMATION 
 
Supplementary Table S1: Default transmission model parameter values and data sources.  
Parameter description Default value / 
range 
Source / 
Reference 
Population characteristics 
Size of population 20,000 
Range: 5,000-25,000 
12 
Rate of exit from the population 0.144 p.a. 
Range: 0.1-0.25 
18 
Untreated active TB prevalence per 
100,000 
100-2,000 Range examined 
Percentage of TB that is MDR at baseline 2%-15% Range examined 
TB natural history 
Percentage of incident infections that are 
slow-progressing 
86% 16 
Per-capita rate of slow progression to 
active TB disease 
1.13×10-4 p.a. 16 
Per-capita rate of fast progression to 
active TB disease 
0.88 p.a. 16 
Percentage of new disease that is smear 
positive 
45% 16 
Per-capita mortality rate of untreated 
active disease 
0.23 p.a. 19 
Per-capita rate of conversion from smear-
negative to positive 
0.015 p.a. 16 
Per-capita rate of self-cure: natural 
reversion from active disease to latent 
infection 
0.21 p.a. 19 
Relative transmissibility of MDR TB 
compare to DS TB 
Fitted Fitted for each 
scenario 
Probability of acquiring MDR TB after 
treatment failure 
3.5% 20 
Screening & treatment 
Per-capita rate of passive case-finding 3.02 p.a. 11 
Per-capita rate of active case-finding by 
Mobile Unit  
0.78 p.a. 11 
Percentage of general population DS TB 
cases treated successfully without ECM 
85% 1 
Percentage of general population MDR 
TB cases treated successfully without 
ECM 
75% 1 
Percentage of homeless DS TB cases 
treated successfully without ECM 
46% 11 
Percentage of homeless MDR TB cases 
treated successfully without ECM 
33% Based on national 
average,1 
Mean duration of successful DS 
treatment 
6 months 13 
Mean duration of unsuccessful DS  and 
RIF-R/MDR treatment 
2 months 21 
Mean duration of successful MDR 
treatment 
20 months 13 
Per-capita mortality rate of unsuccessfully 
treated disease 
0.077 p.a. 16 
Time to culture and DST result 28 days 7 
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Transmission 
Transmission parameter for smear-
positives 
Fitted Fitted 
Relative infectivity of smear-negatives 
(vs. smear-positives) 
0.22 17 
Relative susceptibility of Latent (slow) 
and Recovered patients (vs. susceptibles) 
0.35 16 
Relative infectivity of unsuccessfully 
treated with appropriate regimen (vs. 
untreated) 
0.25 16 
Relative infectivity of treated with 
inappropriate regimen (vs. untreated) 
1 Assumed 
Test performance 
GeneXpert TB sensitivity if patient is 
smear negative 
73% 22 
GeneXpert TB sensitivity if patient is 
smear positive 
98% 22 
GeneXpert TB specificity if patient is 
smear negative or positive 
99% 22 
Specificity of GeneXpert in identifying 
MDR TB 
98% 22 
Sensitivity of GeneXpert in identifying 
MDR TB 
98% 22 
Chest X-ray TB specificity 63% 15 
Chest X-ray TB sensitivity 73% 15 
Sputum smear microscopy TB specificity 77% 23 
Sputum smear microscopy TB sensitivity 53% 23 
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Supplementary Table S2: Economic parameter values and data sources. 
Parameter Value Reference 
Discount rate 3.5% p.a. 14 
Treatment cost: DS TB £4,940 11,24 
Treatment cost: MDR TB £15,683 24 
Clinical examination costs £278 24 
Assisted referral to clinic cost £55.48 25 
Diagnostic culture test cost £22.29 13 
Diagnostic GeneXpert test cost £38.83 27 
Smear microscopy cost £7.64 11 
Annual Mobile Radiology Unit intervention cost £568,909 11 
Mobile Radiology Unit capital cost  £644,019 11 
Digital radiography machine cost £125,275 26 
GeneXpert purchase cost (16-channel)* £145,570 27 
Annual GeneXpert maintenance cost (16-channel)* £8,528 27 
GeneXpert purchase cost (4-channel: 1/4 cost of 16-
channel)* 
£36,392 27, 28. 
Annual GeneXpert maintenance cost (4-channel: 3/8 
cost of 16-channel)* 
£3,198 27,28. 
*Including (20%) Valued Added Tax  
 
 
Supplementary Table S3: QALY parameter values and data sources. 
Health state QoL weight Reference 
Uninfected population 0.87 29 
Any untreated active TB 0.68 30 
Active TB on DS TB treatment 0.81 30 
Active TB on MDR TB treatment 0.68 31 
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Supplementary Figure S1: Active TB disease averted by different active case finding (ACF) 
strategies without enhanced case management in settings with varying TB burden. The impact 
of different ACF strategies on transmission dynamics were compared with current practice in settings 
with different TB prevalence and proportion that is multi-drug/rifampicin resistant (MDR). (a-d) The 
incremental number of averted active TB disease cases was determined over the lifetime of the 
population cohort. (b,c) All individuals screened with GeneXpert wait for their results (no loss to 
follow-up) except for (d) which assumes the GeneXpert only option with a 50% loss to follow-up. 
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Supplementary Figure S2: Active TB disease averted by different active case finding (ACF) 
strategies with enhanced case management in settings with varying TB burden. The impact of 
different ACF strategies on transmission dynamics was compared with current practice in settings with 
different TB prevalence and proportion that is multi-drug/rifampicin resistant (MDR). (a-d) The 
predicted incremental number of averted active TB disease cases was determined over the lifetime of 
the population cohort. (b,c) All individuals screened with GeneXpert wait for their results (no loss to 
follow-up) except for (d) which assumes the GeneXpert only option with a 50% loss to follow-up. 
